Ruby R. Chandy
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Thermo Fisher Outperforms on Life Sciences Recovery. Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
AME: Q3 earnings call set, Citigroup target raised, long-term holdings. AMETEK has announced its third-quarter 2026 earnings call details. Citigroup recently maintained its neutral stance while raising its price target to $263. Other reports focus on the stock's long-term performance over the past 15 years and billionaire Mario Gabelli's decade-long holding of the company. The average analyst target is $282.06.
Transaction History
| DD | ▲ Buy | Grant | 4,030 | $0 | 5/21/2026 | View on chart |
| TMO | ▲ Buy | Grant | 499 | $0 | 5/20/2026 | View on chart |
| DD | ▲ Buy | Grant | 2,794 | $0 | 5/22/2025 | View on chart |
| TMO | ▲ Buy | Grant | 565 | $0 | 5/21/2025 | View on chart |
| DD | ▲ Buy | Grant | 2,109 | $0 | 6/5/2024 | View on chart |
| TMO | ▲ Buy | Grant | 339 | $0 | 5/22/2024 | View on chart |
| DD | ▲ Buy | Grant | 2,566 | $0 | 5/24/2023 | View on chart |
| TMO | ▲ Buy | Grant | 392 | $0 | 5/24/2023 | View on chart |
| DD | ▲ Buy | Grant | 1,000 | $0 | 8/4/2022 | View on chart |
| DD | ▲ Buy | Grant | 2,524 | $170K | 5/26/2022 | View on chart |
| TMO | ▲ Buy | Grant | 369 | $0 | 5/18/2022 | View on chart |
| AME | ▲ Buy | Option Exercise | 5,440 | $255K | 11/16/2021 | View on chart |
| AME | ▼ Sell | Open Market | 1,802 | $256K | 11/16/2021 | View on chart |
| AME | ▲ Buy | Option Exercise | 5,160 | $270K | 11/4/2021 | View on chart |
| AME | ▼ Sell | Open Market | 1,930 | $271K | 11/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DuPont receives analyst upgrades and announces quarterly dividend
DuPont de Nemours was highlighted in several recent analyst reports. RBC Capital kept an Outperform rating while lowering its price target to $160, and Barclays began coverage with an Overweight rating and a $156 target. The company also announced its regular quarterly dividend for common stock. These developments show ongoing analyst attention and a focus on returning cash to shareholders.
DuPont receives analyst upgrades and announces quarterly dividend. DuPont de Nemours was highlighted in several recent analyst reports. RBC Capital kept an Outperform rating while lowering its price target to $160, and Barclays began coverage with an Overweight rating and a $156 target. The company also announced its regular quarterly dividend for common stock. These developments show ongoing analyst attention and a focus on returning cash to shareholders.